HLA-DQA1∗05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysis-Reference-Cited by-同舟云学术

HLA-DQA1∗05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysis

Published:2023-11 Issue:12 Volume:21 Page:3019-3029.e5
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Solitano Virginia,Facciorusso Antonio,McGovern Dermot P.B.,Nguyen Tran,Colman Ruben J.,Zou Lily,Boland Brigid S.,Syversen Silje W.,Jørgensen Kristin Kaasen,Ma Christopher,Armuzzi Alessandro,Wilson Aze,Jairath Vipul,Singh Siddharth^ORCID

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference37 articles.

1. Assessing immunogenicity of biologic drugs in inflammatory joint diseases: progress towards personalized medicine;Gehin;BioDrugs,2022

2. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis;Maneiro;JAMA Intern Med,2013

3. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up;Bartelds;JAMA,2011

4. Anti-drug antibody formation against biologic agents in inflammatory bowel disease: a systematic review and meta-analysis;Bots;BioDrugs,2021

5. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease;Ordas;Clin Gastroenterol Hepatol,2012

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Arthritis complicating inflammatory bowel disease— the future is now;The Lancet Rheumatology;2024-07

2. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study;The Lancet Gastroenterology & Hepatology;2024-06

3. Challenges in IBD Research 2024: Pragmatic Clinical Research;Inflammatory Bowel Diseases;2024-05-01

4. Ustekinumab as alternative for anti-TNFs in HLA-DQA1*05-positive Crohn’s disease;Medicom Conference Report ECCO 2024;2024-04-18

5. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology;Therapeutic Drug Monitoring;2024-04-17